| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jessica A Waller, Fenghua Chen, Connie Sánche. Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. Neuropharmacology. vol 103. 2016-12-13. PMID:26702943. |
the multimodal-acting antidepressant vortioxetine is an antagonist at 5-ht3, 5-ht7, and 5-ht1d receptors, a partial agonist at 5-ht1b receptors, an agonist at 5-ht1a receptors, and an inhibitor of the serotonin (5-ht) transporter (sert) and has pro-cognitive properties. |
2016-12-13 |
2023-08-13 |
Not clear |
| D J David, L Tritschler, J-P Guilloux, A M Gardier, C Sanchez, R Gaillar. [Pharmacological properties of vortioxetine and its pre-clinical consequences]. L'Encephale. vol 42. issue 1 Suppl 1. 2016-12-13. PMID:26879252. |
compared to the ssris, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-ht1d, 5-ht3, 5-ht7 receptor antagonist, 5-ht1b receptor partial agonist and 5-ht1a receptor agonist. |
2016-12-13 |
2023-08-13 |
Not clear |
| R Colle, E Corrubl. [Vortioxetine: a new antidepressant to treat depressive episodes]. L'Encephale. vol 42. issue 1. 2016-10-31. PMID:26358483. |
vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-ht1a, 5-ht1b, 5-ht1d, 5-ht3, 5-ht7 receptors and the serotonin transporter (5-htt). |
2016-10-31 |
2023-08-13 |
Not clear |
| Danielle A Diniz, Júlia Alvarenga Petrocchi, Larissa Caldeira Navarro, Tâmara Cristina Souza, Marina G M Castor, Andrea C Perez, Igor D G Duarte, Thiago R L Romer. Serotonin induces peripheral mechanical antihyperalgesic effects in mice. European journal of pharmacology. vol 767. 2016-10-05. PMID:26460149. |
we used selective antagonists of serotonin receptors (isamoltan 5-ht1b, brl 15572 5-ht1d, ketanserin 5-ht2a, ondansetron 5-ht3 and sb-269970 5-ht7). |
2016-10-05 |
2023-08-13 |
mouse |
| Steven C Leiser, Deborah Iglesias-Bregna, Ligia Westrich, Alan L Pehrson, Connie Sanche. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. Journal of psychopharmacology (Oxford, England). vol 29. issue 10. 2016-06-23. PMID:26174134. |
vortioxetine, a multimodal antidepressant acting through serotonin (5-ht) transporter (sert) inhibition, 5-ht3, 5-ht7 and 5-ht1d receptor antagonism, 5-ht1b receptor partial agonism, and 5-ht1a receptor agonism, had fewer incidences of sleep-related adverse events reported in depressed patients. |
2016-06-23 |
2023-08-13 |
human |
| José-Ángel García-Pedraza, Mónica García, María-Luisa Martín, Asunción Morá. Pharmacological evidence that 5-HT1D activation induces renal vasodilation by NO pathway in rats. Clinical and experimental pharmacology & physiology. vol 42. issue 6. 2016-02-29. PMID:25854421. |
administration (0.00000125 to 0.1 μg/kg) of 5-ct or l-694,247 (5-ht1d agonist) mimicked 5-ht vasodilator effect, while other agonists (1-pbg, α-methyl-5-ht, as-19 (5-ht₇), 8-oh-dpat (5-ht1a) or cgs-12066b (5-ht1b)) did not alter baseline haemodynamic variables. |
2016-02-29 |
2023-08-13 |
rat |
| Mostafa El Mansari, Maurice Lecours, Pierre Blie. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology. vol 232. issue 13. 2016-02-02. PMID:25665528. |
vortioxetine is a novel multimodal antidepressant that is a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist, an inhibitor of the serotonin (5-ht) transporter, and a 5-ht1d, 5-ht3, and 5-ht7 receptor antagonist in vitro. |
2016-02-02 |
2023-08-13 |
rat |
| Vijeta Bobade, Subhash L Bodhankar, Urmila Aswar, Mohan Vishwaraman, Prasad Thakurdesa. Prophylactic effects of asiaticoside-based standardized extract of Centella asiatica (L.) Urban leaves on experimental migraine: Involvement of 5HT1A/1B receptors. Chinese journal of natural medicines. vol 13. issue 4. 2016-01-12. PMID:25908624. |
the interaction of indca with selective 5-ht1a, 5-ht1b, and 5-ht1d receptor antagonists (nan-190, isamoltane hemifumarate, and brl-15572 respectively) against ntg-induced hyperalgesia was also evaluated. |
2016-01-12 |
2023-08-13 |
rat |
| Cécile Bétry, Adeline Etiévant, Alan Pehrson, Connie Sánchez, Nasser Haddjer. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Progress in neuro-psychopharmacology & biological psychiatry. vol 58. 2016-01-05. PMID:25524057. |
vortioxetine is a multimodal acting antidepressant that functions as a 5-ht3 and 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and inhibitor of the 5-ht transporter. |
2016-01-05 |
2023-08-13 |
human |
| Jian-Pu Zheng, Xuemei Zhang, Hao Wang, Yunman Wang, Zhuoan Cheng, Peihao Yin, Wen Pen. Vasomotor dysfunction in the mesenteric artery after organ culture with cyclosporin A. Basic & clinical pharmacology & toxicology. vol 113. issue 6. 2015-11-09. PMID:23809336. |
the results showed that csa increased the mrna expression and contractile function of several g-protein-coupled receptors (gpcrs), such as endothelin receptor type b (etb ), 5-hydroxytryptamine type 1b (5-ht1b ) and 1d (5-ht1d ), in vascular smooth muscle cells. |
2015-11-09 |
2023-08-12 |
rat |
| Stephen M Stah. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS spectrums. vol 20. issue 2. 2015-09-15. PMID:25831967. |
modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (mma): enhancing serotonin release by combining serotonin (5ht) transporter inhibition with actions at 5ht receptors (5ht1a, 5ht1b, 5ht1d, 5ht7 receptors). |
2015-09-15 |
2023-08-13 |
Not clear |
| Ashish Dhir, Jayrajsinh Sarvaiy. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert review of neurotherapeutics. vol 14. issue 12. 2015-09-01. PMID:25418918. |
vortioxetine is an agonist of 5-ht1a, a partial agonist of 5-ht1b and an antagonist of 5-ht1d, 5-ht3 and 5-ht7 serotoninergic receptors. |
2015-09-01 |
2023-08-13 |
Not clear |
| Connie Sanchez, Karen E Asin, Francesc Artiga. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics. vol 145. 2015-08-31. PMID:25016186. |
vortioxetine, a novel antidepressant for the treatment of major depressive disorder (mdd), is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and serotonin (5-ht) transporter (sert) inhibitor. |
2015-08-31 |
2023-08-13 |
Not clear |
| Ligia Westrich, Nasser Haddjeri, Ouria Dkhissi-Benyahya, Connie Sánche. Involvement of 5-HT₇ receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology. vol 89. 2015-07-15. PMID:25446573. |
vortioxetine is a multimodal antidepressant that inhibits 5-ht1d, 5-ht3, 5-ht7 receptor activity, 5-ht reuptake, and enhances the activity of 5-ht1a and 5-ht1b receptors. |
2015-07-15 |
2023-08-13 |
mouse |
| Laurent Tritschler, Daniela Felice, Romain Colle, Jean-Philippe Guilloux, Emmanuelle Corruble, Alain Michel Gardier, Denis Joseph Davi. Vortioxetine for the treatment of major depressive disorder. Expert review of clinical pharmacology. vol 7. issue 6. 2015-06-15. PMID:25166025. |
vortioxetine (brintellix(®), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-ht1a, 5-ht1b, 5-ht1d, 5-ht3, 5-ht7 receptors and the serotonin (5-ht) transporter (5-htt). |
2015-06-15 |
2023-08-13 |
Not clear |
| Elena Dale, Hong Zhang, Steven C Leiser, Yixin Xiao, Dunguo Lu, Charles R Yang, Niels Plath, Connie Sanche. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. Journal of psychopharmacology (Oxford, England). vol 28. issue 10. 2015-06-09. PMID:25122043. |
vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-ht)3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist and a 5-ht transporter (sert) inhibitor. |
2015-06-09 |
2023-08-13 |
rat |
| Ashley Wallace, Alan L Pehrson, Connie Sánchez, David A Morila. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. The international journal of neuropsychopharmacology. vol 17. issue 10. 2015-06-02. PMID:24852131. |
vortioxetine, a novel, multimodal-acting antidepressant, is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist, and inhibits the 5-ht transporter. |
2015-06-02 |
2023-08-13 |
rat |
| S C Leiser, A L Pehrson, P J Robichaud, C Sanche. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. British journal of pharmacology. vol 171. issue 18. 2015-05-26. PMID:24846338. |
vortioxetine is a 5-ht3 , 5-ht7 , and 5-ht1d receptor antagonist, 5-ht1b partial agonist, 5-ht1a agonist, and 5-ht transporter inhibitor. |
2015-05-26 |
2023-08-13 |
rat |
| Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Mor. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clinical practice and epidemiology in mental health : CP & EMH. vol 11. 2015-04-20. PMID:25893002. |
mechanism of action : vortioxetine has 5-ht3, 5-ht7 and 5-ht1d antagonists, 5-ht1b partial agonist and a 5-ht1a agonist and serotonin transporter inhibitor property. |
2015-04-20 |
2023-08-13 |
Not clear |
| Sudhakar Selvaraj, Danilo Arnone, Alessandra Cappai, Oliver Howe. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neuroscience and biobehavioral reviews. vol 45. 2015-04-16. PMID:24971825. |
the evidence for alterations in serotonin transporter availability or other serotonin receptors (5-ht1b; 5-ht1d; 5-ht3; 5-ht4; 5-ht7) is limited. |
2015-04-16 |
2023-08-13 |
Not clear |